Storm hopes to rain on Accent’s parade
Epigenetics has so far failed to live up to the hype. But one UK player, Storm Therapeutics, still hopes to make a mark in a new field, RNA therapeutics.
Why Immatics could soon become the next listed cell therapy player
Immunocore and Adaptimmune could shortly have a publicly listed rival.
Takeda forges another neuroscience deal as Abbvie dips a toe
Takeda's appetite for risk in early stage neuroscience could make it one to watch.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.